Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial

BACKGROUND: No standard maintenance treatment has been obtained to prolong the response duration of soft tissue sarcoma (STS) after first-line chemotherapy. In this study, we aimed to evaluate the efficacy and safety of anlotinib as a maintenance treatment after chemotherapy in STS. METHODS: In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Bushu, Pan, Qiuzhong, Pan, Hua, Li, Haomiao, Li, Xianan, Chen, Jing, Pang, Danmei, Zhang, Baoqing, Weng, Desheng, Peng, Ruiqing, Fang, Meiyu, Zhang, Xing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520347/
https://www.ncbi.nlm.nih.gov/pubmed/37767191
http://dx.doi.org/10.1016/j.eclinm.2023.102240
Descripción
Sumario:BACKGROUND: No standard maintenance treatment has been obtained to prolong the response duration of soft tissue sarcoma (STS) after first-line chemotherapy. In this study, we aimed to evaluate the efficacy and safety of anlotinib as a maintenance treatment after chemotherapy in STS. METHODS: In this multicentre, open-label, single-arm phase 2 trial, patients with advanced STS who achieved partial response or stable disease after first-line anthracycline-based chemotherapy were enrolled between April 2019 and January 2022. All patients received anlotinib as a maintenance treatment. The primary endpoint was progression-free survival (PFS) of anlotinib maintenance treatment. Other endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR) and safety. This study is registered with ClinicalTrials.gov, NCT03890068. FINDINGS: At the data cut-off date (August 8, 2022), 49 patients were enrolled, including 17 with liposarcoma (35%) and 15 with leiomyosarcoma (31%). After a median follow-up of 17.1 months (IQR 9.0–27.2), the median PFS from the beginning of maintenance treatment was 9.1 months (95% CI 5.7–12.5), and the median OS was not reached, and the 1-year OS rate for anlotinib maintenance treatment was 98.0%. The best ORR and DCR were 16% (8/49, 95% CI 7–30) and 94% (46/49, 95% CI 83–99), respectively. Most of the treatment-related adverse events were grade 1–2. Of the grade 3–4 adverse events, the most common were hypertension (10%) and hand-foot syndrome reaction (6%). INTERPRETATION: Postchemotherapy maintenance treatment with anlotinib exhibits promising efficacy and tolerable toxicity in patients with advanced STS. FUNDING: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., the 10.13039/501100012166National Key Research and Development Program of China, and the 10.13039/501100001809National Natural Science Foundation of China.

Ejemplares similares